Old fish farm at sea.
Adobe Stock
The biotechnology company KOA Biotech, based in Barcelona, has announced a €2M funding round, led by Swanlaab Venture Factory, Female Founders's Fund F, and Faber.
The funds will be used to further develop their data-driven technology and biosensors, along with AI-powered analytics to reduce fish mortality, minimize antibiotic dependence, and optimize aquaculture operations.
"A huge thank you to our investors and supporters, and a special mention to our incredible team—your dedication is making this vision a reality," reads the company's statement.
Additionally, Swanlaab published: "Congratulations to Sira Mogas Díez and the entire KOA Biotech team for this great achievement. Their innovative technology provides key solutions for aquaculture, enabling early detection of infections and more sustainable management, reducing the significant losses currently occurring in the sector."
KOA Biotech provides a digital, autonomous, and onsite testing technology for fish farms that reduces fish mortality and can reduce costs by up to 50% in fish farms. Its onsite testing kits continually monitor potentially harmful bacteria in water and create early warning alerts to prevent infections.
The Barcelona-based company is a spinoff of the University of Pompeu Fabra started by a group of PhDs in Biology. It has two live tests running and eight more LOIs set to launch in the next three months.
